Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Sreeraj Vasudevan, Anu Korula, Lingaraj Nayak, Mithun Abraham, Alok Shetty, Parathan Karunakaran, Abhilash Menon, Prasanth Ganesan, Gaurav Prakash, Nishil Gowda, Chepsy Philip, Rayaz Ahmed, Sridharan Srinivasan, Prasanna Samuel, Omprakash Karunamurthy, Chandran Nair, Manju Sengar, Vikram Mathews

Blood (2025) 146 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2025-7154

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Blood (2025) 146 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2025-2829

Published: 2025

Journal Articles

Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India

Blood (2025) 146 (Supplement 1): 5404.

https://doi.org/10.1182/blood-2025-5404

Published: 2025

Journal Articles

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

Blood (2025) 146 (Supplement 1): 8049.

https://doi.org/10.1182/blood-2025-8049

Published: 2025

Journal Articles

Presenting features, treatment patterns and predictors of outcomes in AL amyloidosis at a tertirary care cancer centre

Blood (2025) 146 (Supplement 1): 7501.

https://doi.org/10.1182/blood-2025-7501

Published: 2025

Journal Articles

Outcomes with ATO/ATRA based regimen in apml - steroid induced toxicities are a concern in LMICs

Hasmukh Jain, Manju Sengar, Alok Shetty, Lingaraj Nayak, Bhausaheb Bagal, Girish B S, Meghana C S, Thomas Eipe, Neha Sharma, Vasu Babu

Blood (2025) 146 (Supplement 1): 3460.

https://doi.org/10.1182/blood-2025-3460

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Journal Articles

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

Thomas Eipe, Manju Sengar, Hasmukh Jain, Alok Shetty, Neha Sharma, Lingaraj Nayak, Bhausaheb Bagal

Blood (2025) 146 (Supplement 1): 8251.

https://doi.org/10.1182/blood-2025-8251

Published: 2025

Journal Articles

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Atharva Karulkar, Hasmukh Jain, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Neeraj Siddarthan, Pavan Kumar Boyella, Sanket Shah, Sameer Melinkeri, Anshul Gupta, Prashant Mehta, Chandran Nair, Dinesh Bhurani, Akshay Lahoti, Anupam Chakrapani, Balakrishna Padate, Prakash Shekhawat, Priyanka Samal, Rajat Bajaj, Rumesh Chandar, Padmaja Lokireddy, Anil Aribandi, Bhausaheb Bagal, Girish Badarkhe, Jayachandran P.K., Kripa Bajaj, Nataraj KS, Nishad Dhakate, Rajan Kapoor, Rahul Bhargava, Sameer Tulpule, Sharat Damodar, Sunil Gupta, Suraj Chiraniya, Suvir Singh, Rajasekar Thirugnanam, Vasu Babu Goli, Vikram Mathews, Esha Kaul, Krishna Reddy Golamari, Kannan Subramanian, Lingaraj Nayak, Alok Shetty, Aditya Murali, Punit Jain, Rajat Bhattacharyya, Rakesh Boya, Ram Abhinav, Velu Nair, Hari Menon, Monisha Harimadhavan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayshree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 1076.

https://doi.org/10.1182/blood-2025-1076

Published: 2025

Journal Articles

Baseline characteristics, serological and measurable residual disease responses and outcomes in newly diagnosed multiple myeloma patients not planned for autologous stem cell transplant; Results from a prospective randomised study using MRD guided therapy

Blood (2025) 146 (Supplement 1): 5779.

https://doi.org/10.1182/blood-2025-5779

Published: 2025

Journal Articles

Prognostic Significance of Wilms' Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes

Blood (2024) 144 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2024-199066

Published: 2024

Journal Articles

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Blood (2024) 144 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2024-203645

Published: 2024

Journal Articles

Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2024-199045

Published: 2024

Journal Articles

Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1

Blood (2024) 144 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2024-199037

Published: 2024

Journal Articles

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Blood (2024) 144 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2024-202335

Published: 2024

Journal Articles

Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2953.

https://doi.org/10.1182/blood-2024-199036

Published: 2024

Journal Articles

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

Blood (2024) 144 (Supplement 1): 7203.

https://doi.org/10.1182/blood-2024-201984

Published: 2024

Journal Articles

Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2024-199348

Published: 2024

Journal Articles

Myelodysplasia-Related Mutations in Adults and End-of-Induction Measurable Residual Disease Are Associated with Inferior Outcome in Patients with Acute Leukemia of Ambiguous Lineage

Blood (2024) 144 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2024-202253

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

Presenting features, treatment patterns and predictors of outcomes in AL amyloidosis at a tertirary care cancer centre

Outcomes with ATO/ATRA based regimen in apml - steroid induced toxicities are a concern in LMICs

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Baseline characteristics, serological and measurable residual disease responses and outcomes in newly diagnosed multiple myeloma patients not planned for autologous stem cell transplant; Results from a prospective randomised study using MRD guided therapy

Prognostic Significance of Wilms' Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)

Myelodysplasia-Related Mutations in Adults and End-of-Induction Measurable Residual Disease Are Associated with Inferior Outcome in Patients with Acute Leukemia of Ambiguous Lineage

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only